Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)
Amylyx Pharmaceuticals (AMLX) posted quarterly Preferred Stock Liabilities of $134.8 million for Q4 2021, little changed quarter-over-quarter from $134.8 million in Q3 2021.
Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021) Analysis & Trends
Amylyx Pharmaceuticals' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $134.8 million for Q4 2021.
- In Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $134.8 million; the TTM figure through Dec 2021 stood at $134.8 million (changed N/A YoY), while the FY2021 annual figure was $134.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2021 stood at $134.8 million, roughly flat from $134.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $134.8 million in Q3 2021, with the low at $7.7 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 134.79 Mn |
| Sep 30, 2021 | 134.79 Mn |
| Jun 30, 2021 | 7.68 Mn |
| Mar 31, 2021 | 7.68 Mn |